𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia

✍ Scribed by Wei, Andrew; Tan, Peter

Book ID
126958204
Publisher
Informa plc
Year
2012
Tongue
English
Weight
143 KB
Volume
54
Category
Article
ISSN
1042-8194

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Results of imatinib mesylate therapy in
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated